Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration

2002 ◽  
Vol 37 (3) ◽  
pp. 322-330 ◽  
Author(s):  
Antonio Mazzocca ◽  
Vinicio Carloni ◽  
Silvia Cappadona Sciammetta ◽  
Claudia Cordella ◽  
Pietro Pantaleo ◽  
...  
2011 ◽  
Vol 300 (2) ◽  
pp. G316-G326 ◽  
Author(s):  
Melania Scarpa ◽  
Alessia R. Grillo ◽  
Paola Brun ◽  
Veronica Macchi ◽  
Annalisa Stefani ◽  
...  

Following liver injury, the wound-healing process is characterized by hepatic stellate cell (HSC) activation from the quiescent fat-storing phenotype to a highly proliferative myofibroblast-like phenotype. Snail1 is a transcription factor best known for its ability to trigger epithelial-mesenchymal transition, to influence mesoderm formation during embryonic development, and to favor cell survival. In this study, we evaluated the expression of Snail1 in experimental and human liver fibrosis and analyzed its role in the HSC transdifferentiation process. Liver samples from patients with liver fibrosis and from mice treated by either carbon tetrachloride (CCl4) or thioacetamide (TAA) were evaluated for mRNA expression of Snail1. The transcription factor expression was investigated by immunostaining and real-time quantitative RT-PCR (qRT-PCR) on in vitro and in vivo activated murine HSC. Snail1 knockdown studies on cultured HSC and on CCl4-treated mice were performed by adenoviral delivery of short-hairpin RNA; activation-related genes were quantitated by real-time qRT-PCR and Western blotting. Snail1 mRNA expression resulted upregulated in murine experimental models of liver injury and in human hepatic fibrosis. In vitro studies showed that Snail1 is expressed by HSC and that its transcription is augmented in in vitro and in vivo activated HSC compared with quiescent HSC. At the protein level, we could observe the nuclear translocation of Snail1 in activated HSC. Snail1 knockdown resulted in the downregulation of activation-related genes both in vitro and in vivo. Our data support a role for Snail1 transcription factor in the hepatic wound-healing response and its involvement in the HSC transdifferentiation process.


2012 ◽  
Vol 142 (4) ◽  
pp. 928-937.e3 ◽  
Author(s):  
Abby L. Olsen ◽  
Bridget K. Sackey ◽  
Cezary Marcinkiewicz ◽  
David Boettiger ◽  
Rebecca G. Wells

2003 ◽  
Vol 90 (2) ◽  
pp. 387-396 ◽  
Author(s):  
Fabiana M. da Silva ◽  
Eduardo L.M. Guimarães ◽  
Ivana Grivicich ◽  
Vera Maria T. Trindade ◽  
Regina Maria Guaragna ◽  
...  

Hepatology ◽  
2008 ◽  
Vol 49 (1) ◽  
pp. 227-239 ◽  
Author(s):  
Richard G. Ruddell ◽  
Belinda Knight ◽  
Janina E. E. Tirnitz-Parker ◽  
Barbara Akhurst ◽  
Lesa Summerville ◽  
...  

2020 ◽  
Vol 134 (16) ◽  
pp. 2189-2201
Author(s):  
Jessica P.E. Davis ◽  
Stephen H. Caldwell

Abstract Fibrosis results from a disordered wound healing response within the liver with activated hepatic stellate cells laying down dense, collagen-rich extracellular matrix that eventually restricts liver hepatic synthetic function and causes increased sinusoidal resistance. The end result of progressive fibrosis, cirrhosis, is associated with significant morbidity and mortality as well as tremendous economic burden. Fibrosis can be conceptualized as an aberrant wound healing response analogous to a chronic ankle sprain that is driven by chronic liver injury commonly over decades. Two unique aspects of hepatic fibrosis – the chronic nature of insult required and the liver’s unique ability to regenerate – give an opportunity for pharmacologic intervention to stop or slow the pace of fibrosis in patients early in the course of their liver disease. Two potential biologic mechanisms link together hemostasis and fibrosis: focal parenchymal extinction and direct stellate cell activation by thrombin and Factor Xa. Available translational research further supports the role of thrombosis in fibrosis. In this review, we will summarize what is known about the convergence of hemostatic changes and hepatic fibrosis in chronic liver disease and present current preclinical and clinical data exploring the relationship between the two. We will also present clinical trial data that underscores the potential use of anticoagulant therapy as an antifibrotic factor in liver disease.


2001 ◽  
Vol 120 (5) ◽  
pp. A379-A379
Author(s):  
S FIORUCCI ◽  
E ANTONELLI ◽  
O MORELLI ◽  
A MENCARELLI ◽  
B PALAZZETTI ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document